LOPRESSIDONE Drug Patent Profile

Which patents cover Lopressidone, and when can generic versions of Lopressidone launch?

Lopressidone is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in LOPRESSIDONE is chlorthalidone; metoprolol tartrate. There are twenty-one drug master file entries for this compound. Additional details are available on the chlorthalidone; metoprolol tartrate profile page.

Summary for LOPRESSIDONE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	124
Patent Applications:	3,990
DailyMed Link:	LOPRESSIDONE at DailyMed

US Patents and Regulatory Information for LOPRESSIDONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	LOPRESSIDONE	chlorthalidone; metoprolol tartrate	CAPSULE;ORAL	019451-001	Dec 31, 1987		DISCN	No	No
Novartis	LOPRESSIDONE	chlorthalidone; metoprolol tartrate	CAPSULE;ORAL	019451-002	Dec 31, 1987		DISCN	No	No

Expired US Patents for LOPRESSIDONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	LOPRESSIDONE	chlorthalidone; metoprolol tartrate	CAPSULE;ORAL	019451-001	Dec 31, 1987
Novartis	LOPRESSIDONE	chlorthalidone; metoprolol tartrate	CAPSULE;ORAL	019451-002	Dec 31, 1987

International Patents for LOPRESSIDONE

See the table below for patents covering LOPRESSIDONE around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	2106209
Switzerland	578507
Austria	317181

LOPRESSIDONE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Antipsychotic Drugs: Focus on Ziprasidone

Introduction to Antipsychotic Drugs

Antipsychotic drugs are a crucial class of medications used to treat psychiatric illnesses, including schizophrenia, bipolar disorder, and depression. Among these, ziprasidone, known by the brand name Geodon, is a second-generation atypical antipsychotic that has been gaining significant attention due to its efficacy and safety profile.

Market Overview of Antipsychotic Drugs

The global antipsychotic drugs market is projected to experience substantial growth over the coming years. In 2023, the market was valued at USD 16.14 billion and is expected to grow to USD 26.48 billion by 2032, exhibiting a CAGR of 5.4% during the forecast period[3].

Ziprasidone Market Dynamics

Drivers of Growth

The ziprasidone market is driven by several key factors:

• Rising Cases of Mental Health Disorders: The increasing prevalence of mental health issues such as schizophrenia and bipolar disorder is a significant driver. According to the World Health Organization (WHO), mental disorders are expected to cost the global economy an estimated USD 6.0 trillion by 2030[3].
• Effectiveness and Safety: Ziprasidone is preferred due to its effectiveness in treating schizophrenia and bipolar disorder with relatively fewer side effects on weight and cholesterol levels compared to other antipsychotics[1].
• Convenient Administration: Available in both capsule and liquid suspension forms, ziprasidone offers flexibility in administration, making it more patient-friendly[1].

Regional Outlook

North America dominates the global antipsychotic drugs market, including the ziprasidone segment, due to the strong prevalence of psychiatric illnesses and the presence of prominent biopharmaceutical companies. The region's market size stood at USD 9.98 billion in 2023 and is expected to continue its dominance during the forecast period[3].

Competitive Landscape

The global ziprasidone market is highly competitive, with key players such as Pfizer, Sandoz, Lupin Pharmaceuticals, Mylan Pharmaceuticals, and several Indian pharmaceutical companies like Aurobindo, Macleods Pharmaceuticals, and Zydus Pharmaceuticals. These companies are engaging in various strategies including R&D investments, partnerships, and mergers and acquisitions to strengthen their market positions[1].

Financial Trajectory of Ziprasidone

Market Size and Growth

The global ziprasidone market size was robust in 2021 and is expected to register rapid revenue growth over the forecast period. The market is driven by the increasing demand for ziprasidone in hospitals and drug stores, where it is used as an effective antipsychotic for treating mental disorders[1].

Revenue Projections

The ziprasidone market is anticipated to grow significantly, driven by the rising cases of mental health disorders. The market revenue is expected to increase substantially, contributing to the overall growth of the antipsychotic drugs market, which is projected to reach USD 26.48 billion by 2032[3].

Segmentation and Application

The ziprasidone market is segmented based on method of administration (oral and intramuscular injection) and application (hospitals, drug stores, and others). The oral administration segment is expected to dominate due to its convenience and patient preference[1].

Technological and Product Advancements

The antipsychotic drugs market, including ziprasidone, is witnessing advancements in drug formulations. For instance, the launch of long-acting injectable forms of antipsychotics, such as aripiprazole, is expected to boost market growth. These new formulations offer greater benefits in terms of efficacy and patient compliance[3].

Impact of COVID-19

The COVID-19 pandemic had a positive impact on the antipsychotic drugs market, including ziprasidone, due to the increased adoption of telemedicine for managing psychotic diseases. This shift led to a greater use of these medications to cope with mental health symptoms during the pandemic[3].

Challenges and Restraints

Despite the growth prospects, the ziprasidone market faces challenges such as regulatory hurdles, side effects associated with long-term use, and competition from other antipsychotic drugs. However, the benefits of ziprasidone, including its lower sedation effects and minimal impact on weight and cholesterol, continue to make it a preferred choice among healthcare providers[1].

Key Takeaways

• The global ziprasidone market is driven by the rising cases of mental health disorders and the drug's effectiveness in treating schizophrenia and bipolar disorder.
• North America dominates the market due to the strong prevalence of psychiatric illnesses and the presence of prominent biopharmaceutical companies.
• The market is expected to grow significantly, with a focus on oral and intramuscular administration forms.
• Technological advancements, such as long-acting injectable forms, are expected to boost market growth.
• The COVID-19 pandemic has accelerated the adoption of telemedicine, contributing to the increased use of antipsychotic medications.

FAQs

1. What is the primary driver of the ziprasidone market growth?

The primary driver of the ziprasidone market growth is the increasing prevalence of mental health disorders such as schizophrenia and bipolar disorder.

2. Which region dominates the global antipsychotic drugs market?

North America dominates the global antipsychotic drugs market, including the ziprasidone segment, due to the strong prevalence of psychiatric illnesses and the presence of prominent biopharmaceutical companies.

3. What are the key benefits of ziprasidone over other antipsychotics?

Ziprasidone has relatively fewer side effects on weight and cholesterol levels, causes less sedation, and is available in both oral and intramuscular injection forms, making it a preferred choice.

4. How has the COVID-19 pandemic impacted the antipsychotic drugs market?

The COVID-19 pandemic has positively impacted the market by increasing the adoption of telemedicine for managing psychotic diseases, leading to greater use of antipsychotic medications.

5. What are the expected revenue projections for the ziprasidone market?

The ziprasidone market is expected to register rapid revenue growth over the forecast period, contributing to the overall growth of the antipsychotic drugs market, which is projected to reach USD 26.48 billion by 2032.

Cited Sources:

1. Reports and Data, "Global Ziprasidone Market – Forecast to 2030," Biospace, July 14, 2022.
2. BMJ Open, "LiMiT AKI: A randomized controlled trial of metformin for the prevention of acute kidney injury in patients with sepsis," April 30, 2024.
3. Fortune Business Insights, "Antipsychotic Drugs Market Size, Share | Growth [2024-2032]," Fortune Business Insights.
4. DataM Intelligence, "Ziprasidone Market Size, Share, Industry, Forecast and outlook (2023-2030)," DataM Intelligence, October 2023.
5. GlobeNewswire, "2024 Research Report | Antipsychotic Drugs Market Poised for Significant Growth by 2030," GlobeNewswire, October 14, 2024.